1. Kim YS, Chung WS, Lee SB. The causative organisms and therapy of corneal ulcers. J Korean Ophthalmol Soc. 1994. 35:1171–1177.
2. Park JH, Lee SB. Analysis on inpatients with infectious keratitis: causative organisms, clinical aspects and risk factors. J Korean Ophthalmol Soc. 2009. 50:1152–1166.
3. Levey SB, Katz HR, Abrams DA, et al. The role of cultures in the management of ulcerative keratitis. Cornea. 1997. 16:383–386.
4. Schaefer F, Bruttin O, Zografos L, Guex-Crosier Y. Bacterial keratitis: a prospective clinical and microbiological study. Br J Ophthalmol. 2001. 85:842–847.
5. Armstrong RA. The microbiology of the eye. Ophthalmic Physiol Opt. 2000. 20:429–441.
6. Leck AK, Thomas PA, Hagan M, et al. Aetiology of suppurative corneal ulcers in Ghana and south India, and epidemiology of fungal keratitis. Br J Ophthalmol. 2002. 86:1211–1215.
7. Hahn YH, Lee SJ, Hahn TW, et al. Antibiotic susceptibilities of ocular isolates from patients with bacterial keratitis: a multi-center study. J Korean Ophthalmol Soc. 1999. 40:2401–2410.
8. Jones DB. Decision-making in the management of microbial keratitis. Ophthalmology. 1981. 88:814–820.
9. Baum JL. Initial therapy of suspected microbial corneal ulcers. I. Broad antibiotic therapy based on prevalence of organisms. Surv Ophthalmol. 1979. 24:97–105.
10. Humphreys H, Mulvihill E. Ciprofloxacin-resistant Staphylococcus aureus. Lancet. 1985. 2:383.
11. George RC, Ball LC, Norbury PB. Susceptibility to ciprofloxacin of nosocomial gram-negative bacteria and staphylococci isolated in the UK. J Antimicrob Chemother. 1990. 26:145–156.
12. Raviglione MC, Boyle JF, Mariuz P, et al. Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital. Antimicrob Agents Chemother. 1990. 34:2050–2054.
13. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology. 2000. 107:1497–1502.
14. Kunimoto DY, Sharma S, Garg P, Rao GN. In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin. Emerging resistance. Ophthalmology. 1999. 106:80–85.
15. Garg P, Sharma S, Rao GN. Ciprofloxacin-resistant Pseudomonas keratitis. Ophthalmology. 1999. 106:1319–1323.
16. Srinivasan M, Gonzales CA, George C, et al. Epidemiology and aetiological diagnosis of corneal ulceration in Madurai, south India. Br J Ophthalmol. 1997. 81:965–971.
17. Yeh DL, Stinnett SS, Afshari NA. Analysis of bacterial cultures in infectious keratitis, 1997 to 2004. Am J Ophthalmol. 2006. 142:1066–1068.
18. Zhang C, Liang Y, Deng S, et al. Distribution of bacterial keratitis and emerging resistance to antibiotics in China from 2001 to 2004. Clin Ophthalmol. 2008. 2:575–579.
19. Toshida H, Kogure N, Inoue N, Murakami A. Trends in microbial keratitis in Japan. Eye Contact Lens. 2007. 33:70–73.
20. Liesegang TJ, Forster RK. Spectrum of microbial keratitis in South Florida. Am J Ophthalmol. 1980. 90:38–47.
21. Ahn M, Jung YT, Han HJ. A clinical study on infectious corneal ulcer. J Korean Ophthalmol Soc. 1996. 37:1538–1543.
22. Kim WJ, Kweon EY, Lee DW, et al. Prognostic factor and antibiotic susceptibility in bacterial keratitis: results of an eight-year period. J Korean Ophthalmol Soc. 2009. 50:1495–1504.
23. Lee WC, Lee SY. National health screening program of Korea. J Korean Med Assoc. 2010. 53:363–370.
24. Kirkendall WM, Hammond JJ. Hypertension in the elderly. Arch Intern Med. 1980. 140:1155–1161.
25. Biemer JJ. Antimicrobial susceptibility testing by the Kirby-Bauer disc diffusion method. Ann Clin Lab Sci. 1973. 3:135–140.
26. Jorgensen JH, Hindler JF. New consensus guidelines from the Clinical and Laboratory Standards Institute for antimicrobial susceptibility testing of infrequently isolated or fastidious bacteria. Clin Infect Dis. 2007. 44:280–286.
27. Shin SY, Koo SH, Kwon KC, et al. Evaluation of the Vitek 2 korean antimicrobial susceptibility testing cards AST N056 and AST N055. Korean J Clin Microbiol. 2008. 11:23–28.
28. Sun X, Deng S, Li R, et al. Distribution and shifting trends of bacterial keratitis in north China (1989-98). Br J Ophthalmol. 2004. 88:165–166.
29. Bourcier T, Thomas F, Borderie V, et al. Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases. Br J Ophthalmol. 2003. 87:834–838.
30. Sun HJ, Lee JY, Kim SY, Jung MS. Clinical features of infectious keratits in west coast area of Chungcheongnam-do, Korea. J Korean Ophthalmol Soc. 2010. 51:658–663.
31. Tuft SJ, Matheson M. In vitro antibiotic resistance in bacterial keratitis in London. Br J Ophthalmol. 2000. 84:687–691.
32. Fong CF, Hu FR, Tseng CH, et al. Antibiotic susceptibility of bacterial isolates from bacterial keratitis cases in a university hospital in Taiwan. Am J Ophthalmol. 2007. 144:682–689.
33. Potron A, Poirel L, Bernabeu S, et al. Nosocomial spread of ESBL-positive Enterobacter cloacae co-expressing plasmid-mediated quinolone resistance Qnr determinants in one hospital in France. J Antimicrob Chemother. 2009. 64:653–654.
34. Ahn GS, Hahn YH, Lee HB. Serratia marcescens keratitis. J Korean Ophthalmol Soc. 2002. 43:658–664.
35. Cheng KH, Leung SL, Hoekman HW, et al. Incidence of contact-lens-associated microbial keratitis and its related morbidity. Lancet. 1999. 354:181–185.
36. You IC, Lee SH, Park YG, Yoon KC. Clinical aspect and prognosis of Stenotrophomonas (Xanthomonas) Maltophilia keratitis. J Korean Ophthalmol Soc. 2007. 48:889–897.
37. Jensen HG, Felix C. In Vitro Antibiotic Testing Group. In vitro antibiotic susceptibilities of ocular isolates in North and South America. Cornea. 1998. 17:79–87.
38. Bower KS, Kowalski RP, Gordon YJ. Fluoroquinolones in the treatment of bacterial keratitis. Am J Ophthalmol. 1996. 121:712–715.
39. Kim DH, Stark WJ, O'Brien TP, Dick JD. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Ophthalmology. 2005. 112:1992–1996.
40. Lai WW, Chu KO, Chan KP, et al. Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy. Am J Ophthalmol. 2007. 144:315–318.
41. Mather R, Karenchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002. 133:463–466.
42. Smitha S, Lalitha P, Prajna VN, Srinivasan M. Susceptibility trends of pseudomonas species from corneal ulcers. Indian J Med Microbiol. 2005. 23:168–171.
43. Keseru JS, Gál Z, Barabás G, et al. Investigation of beta-Lactamases in clinical isolates of Staphylococcus aureus for further explanation of borderline methicillin resistance. Chemotherapy. 2005. 51:300–304.
44. Fontana R, Aldegheri M, Ligozzi M, et al. Overproduction of a low-affinity penicillin-binding protein and high-level ampicillin resistance in Enterococcus faecium. Antimicrob Agents Chemother. 1994. 38:1980–1983.
45. Ly CN, Pham JN, Badenoch PR, et al. Bacteria commonly isolated from keratitis specimens retain antibiotic susceptibility to fluoroquinolones and gentamicin plus cephalothin. Clin Experiment Ophthalmol. 2006. 34:44–50.